The 38th Annual Dallas Rhinoplasty Meeting is Also Going Virtual
Dallas plastic surgeon and Meeting Chair, Dr. Rod J. Rohrich, hosts the 38th annual Dallas Rhinoplasty Meeting, to be held March 13, 2021 in new, completely virtual format.
Tag: virtual meeting
All
Popular
All
Latest
The 24th Annual Dallas Cosmetic Surgery and Medicine Meeting is Going Virtual
Dallas plastic surgeon and Meeting Chair, Dr. Rod J. Rohrich, hosts the 2021 Dallas Cosmetic Surgery and Medicine Meeting, to be held March 14, 2021 in completely virtual format.
All
Latest
Where Non-Surgical Aesthetic Spending Is Headed: Inside the $17.5 Billion Aesthetic Shift
Guidepoint Qsight’s Erik Haines breaks down the drivers behind 2024’s $17.5 billion in non-surgical aesthetic spending and what it signals for the future of the industry.
Sun Pharma Presents ODOMZO and LEVULAN KERASTICK + BLU-U Data, Offering Clinical Insights for Treating People with or at Risk of Skin Cancer
A wholly owned subsidiary of Sun Pharmaceutical Industries Ltd presented data analyses for two of its specialty medicines – ODOMZO (sonidegib) and LEVULAN KERASTICK (aminolevulinic acid HCl) + BLU-U – from its dermatology portfolio, providing insights to healthcare providers treating patients who have or are at risk for different types of skin cancer, according to a media release.
Read MoreSun Pharma Announces Long-term Insights into the Clinical Use of ILUMYA (tildrakizumab-asmn) in a Cross Section of People Living with Moderate-to-Severe Plaque Psoriasis
Sun Pharmaceutical Industries Ltd announces in a media release that one of its wholly owned subsidiaries presented further evidence of the long-term use and cost-effectiveness of ILUMYA (tildrakizumab-asmn) in moderate-to-severe plaque psoriasis at the American Academy of Dermatology (AAD) Virtual Meeting Experience 2020.
Read MoreLilly and Dermira Present New Lebrikizumab Phase 2b Clinical Data Showing Patients with Atopic Dermatitis Had Clinically Meaningful Improvements in Itch, Sleep and Quality of Life
Data from this study suggests that treatment with lebrikizumab provided rapid and clinically meaningful improvements in itch, sleep and overall measures of quality of life, according to a media release.
Read MoreAbbVie Presents New Late-Breaking Data Showing SKYRIZI (risankizumab-rzaa) Achieves Superior Rates of Complete Skin Clearance Versus COSENTYX (secukinumab) at 52 Weeks
AbbVie a research-based global biopharmaceutical company, announces new late-breaking Phase 3b head-to-head data showing superior rates of skin clearance for SKYRIZI (risankizumab-rzaa) to COSENTYX (secukinumab) at week 52, in a news release.
Read MoreJohnson & Johnson Consumer Health Presents Findings from Ten-Year Infant and Mother Skin Microbiome Study at American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2020
Johnson & Johnson Consumer Health presented findings from a longitudinal study of infant and mother skin microbiome research at the American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2020, being held from June 12 – 14, 2020, according to a news release.
Read More